Technical Documents

Civil Society Statements


Actions in Brazil

 “We decided to file another patent opposition because the monopoly could be extended from 2017 to 2024, if this patent is granted. The granting of undue patents must be avoided to signal that market strategies seeking unlimited monopoly shall not undermine the sustainability of responses to public health needs”. 

            -- Renata Reis, coordinator of the Working Group on Intellectual Property of the Brazilian Network for the Integration of Peoples (GTPI/ Rebrip)


In Brazil, more than 50,000 people currently take lopinavir + ritonavir. The Working Group on Intellectual Property of the Brazilian Network for the Integration of Peoples (GTPI/ Rebrip) filed an opposition to Abbott patent claims on the medicine’s heat-stable form, which are not novel and do not contribute an inventive step.


Actions to Expand Access to Kaletra in Brazil

GTPI supports judicial decision annulling the patent for a HIV/AIDS medicine (links to www.patentes.org)

Link to press release (November 10, 2011) (em português) from o Grupo de Trabalho Sobre Propriedade Intelectual da Rede Brasiliera pela Integração dos Povos (GTPI/Rebrip)

 

MSF: Brazilians demand greater access to crucial HIV drug (links to msfaccess.org)

Working Group on International Property (GTPI) on Brazilian Patent Office's decision to prioritize examination of the patent application related to heat-stable ritonavir and lopinavir/ritonavir - December 15, 2011 (links to deolhonaspatentes.org.br)

ABIA publishes landscape of patent status and health sanitary registrations for HIV/AIDS treatments in Brazil (jn Portuguese), August 2012

 Essential Action Factsheet- Access to Medicines in Brazil: Interference by the United States, September 21, 2007




Return to the Kaletra Campaign Homepage


Copyright © 2014 Public Citizen. Some rights reserved. Non-commercial use of text and images in which Public Citizen holds the copyright is permitted, with attribution, under the terms and conditions of a Creative Commons License. This Web site is shared by Public Citizen Inc. and Public Citizen Foundation. Learn More about the distinction between these two components of Public Citizen.


Public Citizen, Inc. and Public Citizen Foundation

 

Together, two separate corporate entities called Public Citizen, Inc. and Public Citizen Foundation, Inc., form Public Citizen. Both entities are part of the same overall organization, and this Web site refers to the two organizations collectively as Public Citizen.

Although the work of the two components overlaps, some activities are done by one component and not the other. The primary distinction is with respect to lobbying activity. Public Citizen, Inc., an IRS § 501(c)(4) entity, lobbies Congress to advance Public Citizen’s mission of protecting public health and safety, advancing government transparency, and urging corporate accountability. Public Citizen Foundation, however, is an IRS § 501(c)(3) organization. Accordingly, its ability to engage in lobbying is limited by federal law, but it may receive donations that are tax-deductible by the contributor. Public Citizen Inc. does most of the lobbying activity discussed on the Public Citizen Web site. Public Citizen Foundation performs most of the litigation and education activities discussed on the Web site.

You may make a contribution to Public Citizen, Inc., Public Citizen Foundation, or both. Contributions to both organizations are used to support our public interest work. However, each Public Citizen component will use only the funds contributed directly to it to carry out the activities it conducts as part of Public Citizen’s mission. Only gifts to the Foundation are tax-deductible. Individuals who want to join Public Citizen should make a contribution to Public Citizen, Inc., which will not be tax deductible.

 

To become a member of Public Citizen, click here.
To become a member and make an additional tax-deductible donation to Public Citizen Foundation, click here.